NWBO - Northwest Biotherapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2366
+0.0021 (+0.90%)
As of 3:18PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.2345
Open0.2400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2300 - 0.2450
52 Week Range0.1700 - 0.3700
Volume460,923
Avg. Volume1,373,233
Market Cap123.796M
Beta (3Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-0.2010
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds
    PR Newswirelast month

    NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds

    BETHESDA, Md. , Dec. 14, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, ...

  • NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction
    PR Newswirelast month

    NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction

    The Company will sell most of its UK property to the multi-national corporation. The Company will receive £37.5 million (approximately $47.3 million) cash payment at closing. The Company will retain ownership of 17 acres of the property, which are excluded from the sale and which the Company believes will have substantial additional value in the future.

  • ACCESSWIRE2 months ago

    Growth Opportunities in Stocks Coming Off of Bottoms

    HENDERSON, NV / ACCESSWIRE / November 27, 2018 / With the market in a bit of a swoon, many companies with positive 3 rd quarter announcements have not yet seen them baked into the share price properly. ...

  • ACCESSWIRE2 months ago

    Northwest Biotherapeutics Releases Phase III Data for DCVax(R)-L and Secures New Financing

    DCVax®-L for Glioblastoma is the company's lead product for the treatment of newly diagnosed Glioblastoma. The company stock has moved from $.214 to $.29 in recent days as the company released data from its DCVax®-L phase III study.

  • Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference
    PR Newswire2 months ago

    Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference

    BETHESDA, Md., Nov. 19, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented by Dr. Linda Liau at the 23rd Annual Meeting of the Society for Neuro-Oncology. Patients are continuing to move through time points based on their length of time in the trial.  All of the patients were past the 1-year time point at the time of the 2017 interim data collection, and most of the patients were past the 2-year time point.  The further maturation of the data from March 2017 through October 2018 has provided an opportunity for more patients to reach later time points (3 years and beyond), and enabled a more developed picture of the "long tail" of the survival curve to emerge.  The long tail is a key focus with immune therapies.

  • NW Bio Announces $5 Million Bridge Funding
    PR Newswire2 months ago

    NW Bio Announces $5 Million Bridge Funding

    The notes have a one-year maturity, subject to the Company's right to prepay the loan at any time by paying the principal plus the interest due until maturity, and subject to the holders' rights to require prepayment of the principal and accrued interest after 4 months. The Company also agreed with the Company's CEO, Linda Powers, on further extensions of the Demand Notes relating to the $5.4 million of funding which Ms. Powers provided to the Company in February, March and April of 2018 as a short-term bridge.

  • NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit
    PR Newswire5 months ago

    NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit

    BETHESDA, Md., Aug. 28, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio is presenting at 8:00 pm Wednesday evening, August 29, at the Immuno-Oncology Summit being held at the Seaport World Trade Center, 1 Seaport Boulevard in Boston, Massachusetts.  The title of his presentation is Clinical Development Of Dendritic Cell-Based Immunotherapies for Cancer.  Dr. Bosch will discuss recently published information about the Company's DCVax®-Direct technology.

  • PR Newswire8 months ago

    NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

    BETHESDA, Maryland, June 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company's Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer. Arrangements are being made for Dr. Bosch's presentation to be webcast.  Details will be posted on the Company's website (www.nwbio.com) under the heading "Most Recent Presentations" when the arrangements are completed.  It is anticipated that the webcast will be available for review after the presentation on the Company's website.  This presentation is not an official presentation of the 2018 ASCO Annual Meeting.  It is not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

  • PR Newswire8 months ago

    NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

    BETHESDA, Md., May 31, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company's Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer. Arrangements are being made for Dr. Bosch's presentation to be webcast.  Details will be posted on the Company's website (www.nwbio.com) under the heading "Most Recent Presentations" when the arrangements are completed.  It is anticipated that the webcast will be available for review after the presentation on the Company's website.  This presentation is not an official presentation of the 2018 ASCO Annual Meeting.  It is not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

  • PR Newswire8 months ago

    NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

    BETHESDA, Md., May 29, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research organization managing the trial, tabulated by an independent statistical firm and published with 69 co-authors in the peer reviewed Journal of Translational Medicine (JTM). The trial is ongoing while the data continue to mature, and the Company, the investigators and patients all remain blinded. The interim data set forth in the JTM publication are blinded aggregate data which include patients from both arms of the trial combined: the arm with 2/3 of the patients, who received standard of care plus DCVax-L, and the arm with 1/3 of the patients, who received standard of care plus a placebo.  When the patients experienced tumor recurrence, all patients from both arms were allowed to cross over and start receiving DCVax-L, but without being unblinded as to what they had received before tumor recurrence.  The patient population enrolled in the trial is similar to that in other recent trials, and more than 75% of the patients were over 50 years old (a factor associated with less favorable outcomes).

  • NW Bio Releases Vote Tallies From Special Shareholder Meeting
    PR Newswire9 months ago

    NW Bio Releases Vote Tallies From Special Shareholder Meeting

    BETHESDA, Md., May 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the vote tallies for the three proposals on the ballot at its Special Meeting of Shareholders held last Friday afternoon in Washington, DC. Proposal 1 was to raise the ceiling on the total number of authorized shares of common stock of the Company from 450 million to 1.2 billion.  For this Proposal, only the common shares could vote.  This Proposal was approved, with Yes votes from 87% of the votes cast (245,267,573), with 4% voting against (11,699,346), and 9% abstaining (25,836,335 votes).  30% did not vote (131,861,943). Proposal 2 was to raise the ceiling on the total number of authorized shares of preferred stock of the Company from 40 million to 100 million.  For this Proposal, both the preferred stock and the common stock could vote.  This Proposal was approved with Yes votes from 86% of the votes cast (327,025,901), with 7% voting against (27,266,121), and 7% abstaining (25,796,199).

  • PR Newswire9 months ago

    NW Bio Announces Additional Funding

    On April 26, 2018, the Company and Ms. Powers entered into a note and loan agreement for an additional loan of $1.0 million by Ms. Powers to the Company on the same terms as her prior funding, as previously reported in March.  The Note is convertible into Series B Preferred Stock at $2.30 per share (with each share of Series B Preferred Stock convertible into ten shares of Common Stock at $0.23 per share), and Class D-2 Warrants exercisable for an equal number of shares of Common Stock at $0.30 per share, with warrants on half of the Note repayment amount due and issuable when the loan was provided, and warrants on half of the Note repayment amount due on a proportional basis in the event of conversion of some or all of the Note.

  • ACCESSWIRE11 months ago

    Independent Research on Trending Growth Companies: Northwest Biotherapeutics and Sanuwave Health

    NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Northwest Biotherapeutics, Inc. (OTCQB: NWBO) and Sanuwave Health ...

  • NW Bio Congratulates Cognate BioServices On Its Management Buyout
    PR Newswire11 months ago

    NW Bio Congratulates Cognate BioServices On Its Management Buyout

    BETHESDA, Md., Feb. 20, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, congratulated Cognate BioServices, the contract manufacturer of NWBio's DCVax® products, on the Management Buyout of Cognate supported by global institutional investors, which Cognate announced today. Following this transaction, neither Linda Powers nor any Toucan Capital related entities have any ownership interest in Cognate or any role on Cognate's Board. More information can be found in a Cognate press release at https://www.businesswire.com/news/home/20180220006077/en.